Agenus Inc reports results for the quarter ended December 31 - Earnings Summary

• Agenus Inc AGEN.OQ reported a quarterly adjusted loss of $2.04​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-2.60. The mean expectation of five analysts for the quarter was for a loss of $2.54 per share. Wall Street expected results to range from $-3.40 to $-1.56 per share.

• Revenue fell 68% to $26.84 million from a year ago; analysts expected $30.27 million.

• Agenus Inc's reported EPS for the quarter was a loss of $2.04​.

• The company reported a quarterly loss of $46.81 million.

• Agenus Inc shares had fallen by 21.5% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 3.6% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

Wall Street's median 12-month price target for Agenus Inc is $7.00

This summary was machine generated from LSEG data March 11 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)